Drugs / CD38/CS1 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06574958 | Apr 2024 → Jan 2025 overdue | — | The Second Hospital of Shandong University | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD38/CS1 CAR T cells | “CD38/CS1 CAR T cells, 2.5% human blood albumin, 0.9% sodium chloride injection” NCT06574958 ↗ |
| Action | Deplete | “good killing effect on CD38/CS1 double-positive tumor cells” NCT06574958 ↗ |
| Modality | Cell therapy | “dual-target CAR T cell therapy” NCT06574958 ↗ |
| Route | Intravenous | “Administration mode: intravenous injection” NCT06574958 ↗ |